These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 28412910)

  • 1. Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.
    Tuplin EW; Holahan MR
    Curr Neuropharmacol; 2017 Nov; 15(8):1192-1207. PubMed ID: 28412910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aripiprazole as dopamine partial agonist model: Basic concepts and clinical impact].
    Simon N; Azorin JM
    Encephale; 2018 Dec; 44(6):558-564. PubMed ID: 30466778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
    Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
    Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.
    Newman-Tancredi A; Kleven MS
    Psychopharmacology (Berl); 2011 Aug; 216(4):451-73. PubMed ID: 21394633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology.
    Davies MA; Sheffler DJ; Roth BL
    CNS Drug Rev; 2004; 10(4):317-36. PubMed ID: 15592581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of 5-HT1A receptor agonism in antipsychotic drug action: rationale and perspectives.
    Newman-Tancredi A
    Curr Opin Investig Drugs; 2010 Jul; 11(7):802-12. PubMed ID: 20571976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
    Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
    Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
    Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The atypical antipsychotic, aripiprazole, blocks phencyclidine-induced disruption of prepulse inhibition in mice.
    Fejgin K; Safonov S; Pålsson E; Wass C; Engel JA; Svensson L; Klamer D
    Psychopharmacology (Berl); 2007 Apr; 191(2):377-85. PubMed ID: 17235612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
    Shapiro DA; Renock S; Arrington E; Chiodo LA; Liu LX; Sibley DR; Roth BL; Mailman R
    Neuropsychopharmacology; 2003 Aug; 28(8):1400-11. PubMed ID: 12784105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?
    Mailman RB; Murthy V
    Curr Pharm Des; 2010; 16(5):488-501. PubMed ID: 19909227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aripiprazole: An FDA Approved Bioactive Compound to Treat Schizophrenia- A Mini Review.
    Kumar A; Singh H; Mishra A; Mishra AK
    Curr Drug Discov Technol; 2020; 17(1):23-29. PubMed ID: 30306873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole in the treatment of schizophrenia: a consensus report produced by schizophrenia experts in Italy.
    Cassano GB; Fagiolini A; Lattanzi L; Monteleone P; Niolu C; Sacchetti E; Siracusano A; Vita A
    Clin Drug Investig; 2007; 27(1):1-13. PubMed ID: 17177576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of aripiprazole for delirium in the elderly: a short review.
    Kirino E
    Psychogeriatrics; 2015 Mar; 15(1):75-84. PubMed ID: 25514894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.